Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 30th:
Karyopharm Therapeutics Inc. (KPTI): This pharmaceutical company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.8% over the last 60 days.
Karyopharm Therapeutics Inc. Price and Consensus
Karyopharm Therapeutics Inc. price-consensus-chart | Karyopharm Therapeutics Inc. Quote
Karyopharm's shares gained 16% over the last one month compared to S&P 500’s rise of 14.8%. The company possesses a Momentum Score of A.
Karyopharm Therapeutics Inc. Price
Karyopharm Therapeutics Inc. price | Karyopharm Therapeutics Inc. Quote
Compugen Ltd. (CGEN): This therapeutic discovery company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.2% over the last 60 days.
Compugen Ltd. Price and Consensus
Compugen Ltd. price-consensus-chart | Compugen Ltd. Quote
Compugen’s shares gained more than 100% over the last one month. The company possesses a Momentum Score of A.
Compugen Ltd. Price
Compugen Ltd. price | Compugen Ltd. Quote
AngloGold Ashanti Limited (AU): This gold mining company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.3% over the last 60 days.
AngloGold Ashanti Limited Price and Consensus
AngloGold Ashanti Limited price-consensus-chart | AngloGold Ashanti Limited Quote
AngloGold’s shares gained 40.8% over the last one month. The company possesses a Momentum Score of A.
AngloGold Ashanti Limited Price
AngloGold Ashanti Limited price | AngloGold Ashanti Limited Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Karyopharm Therapeutics Inc. (KPTI): Free Stock Analysis Report
Compugen Ltd. (CGEN): Free Stock Analysis Report
AngloGold Ashanti Limited (AU): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
